Ledadotin 

Ledadotin is a drug-linker conjugate for ADC. Ledadotin consists of a Microtubule inhibitor (Auristatin F-hydroxypropylamide) (HY-P5191) and a linker (BCN-PEG2-Gly-NH-tri(βAla-GGGG-Ser(mPEG8)-βAla-γGlu-Ala)) (HY-177562). Ledadotin can be used for synthesis of ADC Emiltatug ledadotin (HY-177542)^[1].

6357.36

C₂₉₄H₄₉₄N₅₂O₁₀₀

2669084-60-8

O=C(NCCC(NCC(NCC(NCC(NCC(N[C@H](C(NCCOCCOCCOCCOCCOCCOCCOCCOC)=O)COC(NCCC(N[C@H](C(O)=O)CCC(N[C@H](C(OCCCNC([C@@H](CC1=CC=CC=C1)NC([C@H]([C@H](OC)[C@H]2CCCN2C(C[C@@H]([C@@H]([C@@H](CC)C)N(C([C@@H](C(C)C)NC([C@@H](C(C)C)N(C)C)=O)=O)C)OC)=O)C)=O)=O)=O)C)=O)=O)=O)=O)=O)=O)=O)=O)CCOCC(COCCC(NCCC(NCC(NCC(NCC(NCC(N[C@H](C(NCCOCCOCCOCCOCCOCCOCCOCCOC)=O)COC(NCCC(N[C@H](C(O)=O)CCC(N[C@H](C(OCCCNC([C@@H](CC3=CC=CC=C3)NC([C@H]([C@H](OC)[C@H]4CCCN4C(C[C@@H]([C@@H]([C@@H](CC)C)N(C([C@@H](C(C)C)NC([C@@H](C(C)C)N(C)C)=O)=O)C)OC)=O)C)=O)=O)=O)C)=O)=O)=O)=O)=O)=O)=O)=O)=O)(COCCC(NCCC(NCC(NCC(NCC(NCC(N[C@H](C(NCCOCCOCCOCCOCCOCCOCCOCCOC)=O)COC(NCCC(N[C@H](C(O)=O)CCC(N[C@H](C(OCCCNC([C@@H](CC5=CC=CC=C5)NC([C@H]([C@H](OC)[C@H]6CCCN6C(C[C@@H]([C@@H]([C@@H](CC)C)N(C([C@@H](C(C)C)NC([C@@H](C(C)C)N(C)C)=O)=O)C)OC)=O)C)=O)=O)=O)C)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC(CNC(CCC(NCCOCCOCCNC(OC[C@H]7[C@]8(CCC#CCC[C@]87[H])[H])=O)=O)=O)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Toader D, et al. Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody-Drug Conjugate for the Treatment of Cancer. Mol Cancer Ther. 2023 Sep 5;22(9):999-1012.  [Content Brief]